Barinthus Biotherapeutics Plc. ADR’s (BRNS) Stock: A 61.03% Annual Performance Rate

In the past week, BRNS stock has gone up by 21.25%, with a monthly decline of -1.36% and a quarterly plunge of -21.35%. The volatility ratio for the week is 9.52%, and the volatility levels for the last 30 days are 9.34% for Barinthus Biotherapeutics Plc. ADR The simple moving average for the past 20 days is 15.46% for BRNS’s stock, with a 5.78% simple moving average for the past 200 days.

Is It Worth Investing in Barinthus Biotherapeutics Plc. ADR (NASDAQ: BRNS) Right Now?

The stock has a 36-month beta value of -0.52. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The public float for BRNS is 35.31M, and at present, short sellers hold a 0.03% of that float. On April 04, 2024, the average trading volume of BRNS was 15.21K shares.

BRNS) stock’s latest price update

The stock price of Barinthus Biotherapeutics Plc. ADR (NASDAQ: BRNS) has jumped by 22.78 compared to previous close of 2.37. Despite this, the company has seen a gain of 21.25% in its stock price over the last five trading days.

Analysts’ Opinion of BRNS

Morgan Stanley, on the other hand, stated in their research note that they expect to see BRNS reach a price target of $22. The rating they have provided for BRNS stocks is “Overweight” according to the report published on May 25th, 2021.

Jefferies gave a rating of “Buy” to BRNS, setting the target price at $28 in the report published on May 25th of the previous year.

BRNS Trading at 10.09% from the 50-Day Moving Average

After a stumble in the market that brought BRNS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.94% of loss for the given period.

Volatility was left at 9.34%, however, over the last 30 days, the volatility rate increased by 9.52%, as shares sank -4.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.59% lower at present.

During the last 5 trading sessions, BRNS rose by +21.25%, which changed the moving average for the period of 200-days by +16.87% in comparison to the 20-day moving average, which settled at $2.51. In addition, Barinthus Biotherapeutics Plc. ADR saw -21.14% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BRNS starting from Scheeren Joseph, who purchase 10,000 shares at the price of $2.44 back on Jun 26 ’23. After this action, Scheeren Joseph now owns 23,000 shares of Barinthus Biotherapeutics Plc. ADR, valued at $24,400 using the latest closing price.

Wright Robin, the Director of Barinthus Biotherapeutics Plc. ADR, purchase 13,750 shares at $2.66 during a trade that took place back on May 25 ’23, which means that Wright Robin is holding 48,256 shares at $36,612 based on the most recent closing price.

Stock Fundamentals for BRNS

Current profitability levels for the company are sitting at:

  • -108.52 for the present operating margin
  • -4.65 for the gross margin

The net margin for Barinthus Biotherapeutics Plc. ADR stands at -91.64. The total capital return value is set at -0.43. Equity return is now at value -34.28, with -29.18 for asset returns.

Based on Barinthus Biotherapeutics Plc. ADR (BRNS), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -3.92. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -3101.62.

Currently, EBITDA for the company is -71.06 million with net debt to EBITDA at 1.82. When we switch over and look at the enterprise to sales, we see a ratio of -20.77. The receivables turnover for the company is 0.16for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.45.

Conclusion

To sum up, Barinthus Biotherapeutics Plc. ADR (BRNS) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts